Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index climbing 3.3% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.9%.
The iShares Biotechnology ETF (IBB) added 2.4%.
In corporate news, Eli Lilly (LLY) shares climbed 5.1% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments